MicroRNAs have highlighted new regulatory aspects of blood pressure control.
Array-based studies identified many microRNAs that are dysregulated in hypertension.
Circulating microRNAs are excellent candidate biomarkers in hypertension.
MicroRNA biomarkers of target-organ damage show the greatest potential.
Technical challenges remain before microRNA biomarkers can enter clinical practice.